[go: up one dir, main page]

EA201600002A1 - Производные пролекарства замещенных триазолопиридинов - Google Patents

Производные пролекарства замещенных триазолопиридинов

Info

Publication number
EA201600002A1
EA201600002A1 EA201600002A EA201600002A EA201600002A1 EA 201600002 A1 EA201600002 A1 EA 201600002A1 EA 201600002 A EA201600002 A EA 201600002A EA 201600002 A EA201600002 A EA 201600002A EA 201600002 A1 EA201600002 A1 EA 201600002A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
triazolopiridines
substituted
mps
diseases
Prior art date
Application number
EA201600002A
Other languages
English (en)
Inventor
Фолькер Шульце
Ханс-Георг Лерхен
Дональд Бирер
Антье Маргрет Венгнер
Герхард Зимайстер
Филип Линау
Урзула Кренц
Дирк Коземунд
Детлеф Штёкигт
Михаель Брюнинг
Ульрих Люкинг
Ильдико Теребези
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201600002A1 publication Critical patent/EA201600002A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к производным пролекарств ингибиторов Mps-1 киназы формулы (I), к способам их получения, а также к их применению для лечения и/или профилактики заболеваний.
EA201600002A 2013-06-11 2014-06-06 Производные пролекарства замещенных триазолопиридинов EA201600002A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11
PCT/EP2014/061779 WO2014198647A2 (en) 2013-06-11 2014-06-06 Prodrug derivatives of substituted triazolopyridines

Publications (1)

Publication Number Publication Date
EA201600002A1 true EA201600002A1 (ru) 2016-06-30

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600002A EA201600002A1 (ru) 2013-06-11 2014-06-06 Производные пролекарства замещенных триазолопиридинов

Country Status (35)

Country Link
US (1) US9586958B2 (ru)
EP (1) EP3008062B1 (ru)
JP (1) JP2016526534A (ru)
KR (1) KR20160019492A (ru)
CN (1) CN105377848A (ru)
AP (1) AP2015008898A0 (ru)
AR (1) AR096585A1 (ru)
AU (1) AU2014280356A1 (ru)
CA (1) CA2914745A1 (ru)
CL (1) CL2015003605A1 (ru)
CR (1) CR20150659A (ru)
CU (1) CU20150176A7 (ru)
DK (1) DK3008062T3 (ru)
DO (1) DOP2015000299A (ru)
EA (1) EA201600002A1 (ru)
ES (1) ES2626790T3 (ru)
HK (1) HK1221955A1 (ru)
HR (1) HRP20170717T1 (ru)
HU (1) HUE033131T2 (ru)
IL (1) IL242847A0 (ru)
LT (1) LT3008062T (ru)
MA (1) MA38654B1 (ru)
MX (1) MX2015017119A (ru)
NI (1) NI201500176A (ru)
PE (1) PE20160156A1 (ru)
PH (1) PH12015502746A1 (ru)
PL (1) PL3008062T3 (ru)
PT (1) PT3008062T (ru)
RS (1) RS56034B1 (ru)
SG (1) SG11201509858QA (ru)
SI (1) SI3008062T1 (ru)
TN (1) TN2015000545A1 (ru)
UY (1) UY35610A (ru)
WO (1) WO2014198647A2 (ru)
ZA (1) ZA201508868B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
DK3283642T3 (da) 2015-04-17 2024-01-02 Crossfire Oncology Holding B V Prognostiske biomarkører til ttk-hæmmerbaseret kemoterapi
WO2017176620A2 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
JP2024546977A (ja) * 2021-12-15 2024-12-26 シルラジェン，インコーポレイテッド 新生物疾患の処置方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
EP1001945B1 (en) 1997-05-28 2011-03-02 Aventis Pharmaceuticals Inc. QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
CA2582482A1 (en) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
WO2007138072A2 (en) 2006-05-31 2007-12-06 Galapagos N.V. Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
AU2007291190A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
EP2150255A4 (en) 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
AU2008277628B2 (en) 2007-07-18 2012-03-15 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
CN103298814A (zh) 2007-08-23 2013-09-11 阿斯利康(瑞典)有限公司 作为治疗增殖性疾病的ttk/mps1抑制剂的2-苯胺基嘌呤-8-酮
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2222674B8 (en) 2007-11-27 2016-01-06 Cellzome Limited Amino triazoles as pi3k inhibitors
CA2725014C (en) 2008-05-30 2014-06-17 Amgen Inc. Inhibitors of pi3 kinase
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EA201101188A1 (ru) 2009-02-13 2012-04-30 Фовеа Фармасьютикалз [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы
WO2010124826A1 (en) 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
PH12012501381A1 (en) 2010-01-15 2012-10-22 Janssen Pharmaceuticals Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
DK2699575T3 (da) * 2011-04-21 2015-06-22 Bayer Ip Gmbh Triazolopyridiner
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
EP2825540B1 (en) 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
BR112015000308A2 (pt) * 2012-07-10 2017-06-27 Bayer Pharma AG método para preparo de triazolopiridinas substituídas
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
MX2015017011A (es) * 2013-06-10 2016-04-25 Bayer Pharma AG Compuestos nuevos para el tratamiento del cancer.
US20160128988A1 (en) * 2013-06-11 2016-05-12 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor

Also Published As

Publication number Publication date
UY35610A (es) 2015-01-30
CN105377848A (zh) 2016-03-02
CR20150659A (es) 2016-01-29
MX2015017119A (es) 2016-04-06
US9586958B2 (en) 2017-03-07
TN2015000545A1 (en) 2017-04-06
EP3008062A2 (en) 2016-04-20
HRP20170717T1 (hr) 2017-07-28
WO2014198647A2 (en) 2014-12-18
WO2014198647A3 (en) 2015-02-05
HK1221955A1 (zh) 2017-06-16
PL3008062T3 (pl) 2017-08-31
CL2015003605A1 (es) 2016-06-24
PH12015502746A1 (en) 2016-03-21
SI3008062T1 (sl) 2017-06-30
CA2914745A1 (en) 2014-12-18
AU2014280356A1 (en) 2015-12-24
ZA201508868B (en) 2017-08-30
US20160207915A1 (en) 2016-07-21
RS56034B1 (sr) 2017-09-29
SG11201509858QA (en) 2015-12-30
DOP2015000299A (es) 2016-03-15
DK3008062T3 (en) 2017-06-12
IL242847A0 (en) 2016-02-01
LT3008062T (lt) 2017-06-12
EP3008062B1 (en) 2017-04-05
PE20160156A1 (es) 2016-04-20
KR20160019492A (ko) 2016-02-19
HUE033131T2 (en) 2017-11-28
ES2626790T3 (es) 2017-07-26
MA38654B1 (fr) 2018-11-30
CU20150176A7 (es) 2016-05-30
AP2015008898A0 (en) 2015-12-31
NI201500176A (es) 2016-01-06
PT3008062T (pt) 2017-06-07
JP2016526534A (ja) 2016-09-05
AR096585A1 (es) 2016-01-20

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201590748A1 (ru) Противовирусные соединения против rsv
MX2015005015A (es) Inhibidores heteroarilo de pde4.
UA117958C2 (uk) Похідні хіноксаліну, корисні як модулятори кінази fgfr
EA201690752A1 (ru) Ингибиторы g12c kras
EA201691354A1 (ru) Терапевтические ингибирующие соединения
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201690844A1 (ru) Ингибиторы gsk-3
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
EA201691141A1 (ru) Соединения против ccr6
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)